# Determining Upper Limit of Alanine Aminotransferase in Iranian Cohort Population Using Ultrasound Screening for Liver Diseases

**Authors:** Behnam Ahmadi, Farhad Naleini, Mehdi Moradinazar, Bita Anvari

PMC · DOI: 10.34172/mejdd.2025.426 · Middle East Journal of Digestive Diseases · 2025-07-30

## TL;DR

This study determines the upper normal level of ALT for the Iranian population using ultrasound screening to exclude liver disease in a large cohort.

## Contribution

The study establishes a localized ALT upper limit for Iranians by using ultrasound and excluding liver disease cases.

## Key findings

- The 95th percentile of ALT was 29 U/L for women and 36 U/L for men after excluding liver disease.
- Metabolic dysfunction-associated steatotic liver disease (MASLD) was the most common liver disease identified.
- The calculated ALT thresholds were lower than the standard cut-off values currently used.

## Abstract

Alanine aminotransferase (ALT) has a variable normal range according to race and ethnicity. So, the upper normal level of ALT localized for the Iranian population was determined in the Ravansar Non-Communicable Disease (RaNCD) cohort population by re-evaluation of high-risk people.

A cohort population with normal ALT results based on the current kit was checked for a history of liver diseases. After excluding them, the remaining population was included in the distribution diagram of individuals with apparently healthy livers. Participants whose ALT values were in the 90th to 100th percentile were re-evaluated by ultrasonography (US) and a checklist of liver disease. Patients identified as having liver disease or those with other abnormal liver enzymes were excluded, and the 95th percentile was extracted from the distribution diagram of the remaining population.

After excluding liver disease, among 8046 participants of RaNCD, US and re-evaluation were performed in 543 high-risk individuals. Liver disease was diagnosed in 74.6% by US. The most common liver disease was metabolic dysfunction-associated steatotic liver disease (MASLD), accounting for 69.7%. Grade 2 or 3 of MASLD was found in 23.2%. After excluding patients with abnormal liver enzymes and liver disease, the 95th percentile of ALT was 29 U/L in women (sensitivity: 53%, specificity: 82%) and 36 U/L in men (sensitivity: 28%, specificity: 90%).

The calculated 95th percentile was lower than the routine cut-off value of the current kit in both sexes. Generalizability is a significant advantage of our results, provided by the lack of exclusion of patients with metabolic risk factors and the use of US to exclude MASLD.

## Linked entities

- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), MASLD (MONDO:0013209)

## Full-text entities

- **Genes:** GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}
- **Diseases:** congestive heart failure (MESH:D006333), obese (MESH:D009765), inflammatory bowel disease (MESH:D015212), splenomegaly (MESH:D013163), Fatty liver (MESH:D005234), alcoholic liver disease (MESH:D008108), thyroid disease (MESH:D013959), non-Hodgkin lymphoma (MESH:D008228), overweight (MESH:D050177), liver cyst (MESH:D017093), Non-Communicable Disease (MESH:D000073296), cholangiocarcinoma (MESH:D018281), autoimmune or drug induced hepatitis (MESH:D056486), chronic hepatitis B infection (MESH:D019694), polycystic kidney disease (MESH:D007690), hematological malignancies (MESH:D019337), hemangioma (MESH:D006391), hepatocellular carcinoma (MESH:D006528), metabolic dysfunction (MESH:D008659), cyst (MESH:D003560), sclerosing cholangitis (MESH:D015209), hepatocyte damage (MESH:D020263), Wilson disease (MESH:D006527), Hemochromatosis (MESH:D006432), celiac disease (MESH:D002446), autoimmune hepatitis (MESH:D019693), mass (MESH:C536030), cirrhosis (MESH:D005355), hyperlipidemia (MESH:D006949), hepatic metastasis (MESH:D009362), metabolic syndrome (MESH:D024821), hepatocyte injury (MESH:D014947), portal hypertension (MESH:D006975), Liver disease (MESH:D008107), lichen planus (MESH:D008010), fatty (MESH:D008067), leukemia (MESH:D007938), Hepatomegaly (MESH:D006529), viral hepatitis (MESH:D014777), colon cancer (MESH:D015179), extrahepatic biliary stricture (MESH:D001656), hypertension (MESH:D006973), dyslipidemia (MESH:D050171), Diabetes (MESH:D003920), cancers (MESH:D009369), hepatosplenomegaly (MESH:C535727), hepatitis B (MESH:D006509), hepatitis C (MESH:D019698), prediabetes (MESH:D011236)
- **Chemicals:** Alcohol (MESH:D000438), tenofovir (MESH:D000068698), carbohydrate (MESH:D002241)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958307/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958307/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958307/full.md

---
Source: https://tomesphere.com/paper/PMC12958307